Walder Wyss has advised BC Platforms, an expert of data science solutions for personalized healthcare, drug discovery and life science research, in connection with the CHF 20 million (approx. USD 20 million) growth financing round. This growth
Tags :Alexander Gutmans
The groupe. id has been acquired by German private equity firm Elvaston Capital Management. Based in La Chaux-de-Fonds and also present in Yverdon-les-Bains, the groupe.id is a renowed Swiss provider of enterprise resource planning
Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
DSM and Firmenich have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. The Dutch specialty chemicals maker has said that this merge with Swiss
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from
kooky, a brand of Zurich-based CEBS, focuses on developing alternative solutions for disposable tableware, has secured an addition EURO 6 million for expansion to Germany and Austria. Early-stage venture capital fund, UVC Partners acted as main
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
